<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000060</url>
  </required_header>
  <id_info>
    <org_study_id>UT 101</org_study_id>
    <nct_id>NCT05000060</nct_id>
  </id_info>
  <brief_title>Restart TICrH AP Pilot Trial</brief_title>
  <official_title>A Prospective Randomized Open-Label Blinded Endpoint (PROBE) Pilot Trial of Early Restarting Antiplatelet Therapy Versus Usual Care After Traumatic Intracranial Hemorrhage.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas at Austin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas at Austin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective Randomized Open-Label Blinded Endpoint (PROBE) Pilot Trial of restarting&#xD;
      antiplatelet therapy at 1 week versus 3 weeks after traumatic intracranial hemorrhage with a&#xD;
      primary composite endpoint of major bleeding and vascular occlusive events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective Randomized Open Label Blinded Endpoint pilot trial of 100 patients</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded assessment and adjudication of endpoints</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>major bleeding</measure>
    <time_frame>60 days</time_frame>
    <description>Recurrent ICrH or other major bleeding defined by BARC3A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Vascular Occlusive events</measure>
    <time_frame>Baseline (gambles performed pre-randomization)</time_frame>
    <description>Ischemic stroke; myocardial infarction; mesenteric ischemia; peripheral arterial occlusion; deep vein thrombosis; pulmonary embolism; and carotid, coronary, or peripheral arterial revascularization procedures. Major vascular events defined by the Antithrombotic Trialists' Collaboration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Traumatic Intracranial Hemorrhage</condition>
  <arm_group>
    <arm_group_label>1 week restart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Restart of mono or dual antiplatelet therapy one week post injury in TICrH patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 week restart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual Care for restart of mono or dual antiplatelet therapy after TICrH at clinician's discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Timing/1 week</intervention_name>
    <description>Time of restart of antiplatelet therapy is one week after injury</description>
    <arm_group_label>1 week restart</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Timing/3 weeks</intervention_name>
    <description>Time of restart of antiplatelet therapy is left to treating clinician discretion</description>
    <arm_group_label>3 week restart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute traumatic intracranial hemorrhage on either mono or dual antiplatelet therapy&#xD;
&#xD;
          2. History of stroke, vascular stent or coronary or peripheral arterial disease as&#xD;
             indication for antiplatelet *Restarting dual platelet therapy requires one of the&#xD;
             following indications: 1) Acute myocardial infarction in the last year; 2) Coronary&#xD;
             stent in the last year; 3) Non-cardioembolic stroke in the last 21 days (with switch&#xD;
             to monotherapy at 21 days post stroke) 4) Peripheral arterial stent in the past month&#xD;
             (with switch to monotherapy at one month post stent placement).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. SDH &gt;8 mm maximum width or any midline shift at any time point or more than one SDH&#xD;
&#xD;
          2. Physician plan to start/restart anticoagulant therapy during trial period&#xD;
&#xD;
          3. Abbreviated Injury Scale other than head &gt;3&#xD;
&#xD;
          4. Pregnancy&#xD;
&#xD;
          5. Inability to understand need for adherence to study protocol&#xD;
&#xD;
          6. Any active pathological bleeding (no acute blood on most recent CT)&#xD;
&#xD;
          7. Hypersensitivity to drug or other label contraindication&#xD;
&#xD;
          8. Any bleeding that the investigator deems unsafe to restart at 1 week post injury&#xD;
&#xD;
          9. Inability to swallow&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Truman J Milling, MD</last_name>
    <phone>15124969742</phone>
    <email>tjmilling@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashkan J Shoamanesh, MD PhD</last_name>
    <email>ashkan.shoamanesh@phri.ca</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas at Austin</investigator_affiliation>
    <investigator_full_name>Truman J Milling Jr</investigator_full_name>
    <investigator_title>Research Director SDMS Stroke Institute</investigator_title>
  </responsible_party>
  <keyword>restart</keyword>
  <keyword>antiplatelet</keyword>
  <keyword>traumatic intracranial hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Intracranial Hemorrhage, Traumatic</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing with NIH BIOLINCC</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>2 years from study launch</ipd_time_frame>
    <ipd_access_criteria>per NIH policy</ipd_access_criteria>
    <ipd_url>https://biolincc.nhlbi.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

